GILD Nov 2024 72.500 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 09:57AM EDT. Market open.
| Previous close | 2.0800 |
| Open | 2.1600 |
| Bid | 2.4500 |
| Ask | 2.5400 |
| Strike | 72.50 |
| Expiry date | 2024-11-15 |
| Day's range | 2.1600 - 2.4500 |
| Contract range | N/A |
| Volume | |
| Open interest | 4.69k |
Yahoo FinanceOne stock is dragging down the S&P 500's earnings growth
S&P 500 companies have had a solid Q1 earnings season, with one key exception: drugmaker Bristol Myers Squibb.
ZacksGilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Business WireKite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
REDWOOD CITY, Calif. & SANTA MONICA, Calif., May 09, 2024--Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX) today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program. Anito-cel is the first BCMA CAR T to be investigated in multiple myeloma that utilizes Arcellx’s novel and compact D-Domain binder.
© 2024 Yahoo. All rights reserved.